Startup Claims Revolutionary Drug Can Rejuvenate Your Blood

This month, I was approached by Generation Lab, a startup making bold claims about a new anti-aging treatment they call 1-Generation. This injectable therapy combines two existing drugs, supposedly capable of reversing the effects of aging in the bloodstream and revitalizing multiple bodily tissues.

CEO Alina Su highlighted that the treatment is being offered to a select group of individuals under close medical supervision, creating buzz around its potential efficacy. "There’s a long wait list including a lot of celebrities and well-known figures," she noted during our conversation, suggesting that the excitement surrounding this product is palpable.

Despite the allure of such a promising anti-aging solution, skepticism looms large. Generation Lab has not disclosed the specific drugs involved, raising concerns about the legitimacy of their claims. My intrigue, however, stems from my long-standing interest in the work of Irina Conboy, the scientific mind behind Generation Lab. Conboy is known for her research involving parabiosis, a technique where the circulatory systems of young and old lab animals are joined together.

Conboy's research indicates that young blood carries rejuvenating properties, but practically replicating this effect in humans has proven elusive. In her recent work, she asserts that she has managed to harness the benefits of youthful blood without the need for direct blood exchange, which could revolutionize the field of longevity medicine.

Over the past few months, Conboy has reportedly experienced increased vitality from the treatment, alongside other participants, including Su and Conboy's husband, Michael. Anecdotal reports suggest various benefits, such as improved vision and enhanced physical endurance. However, such claims require rigorous scientific validation.

While the prospect of an effective age-reversal drug is enticing, the history of similar claims is fraught with disappointment. Generation Lab's proposed larger study, which they intend to conduct with participants who will pay for their enrollment, raises further questions about the integrity of the research. Such pay-to-play models often blur the line between legitimate scientific inquiry and marketing ploys.

The study is to be led by alternative medicine practitioners, including Matt Cook, who has a contentious reputation due to his association with unproven therapies. Cook's initial skepticism about the treatment's efficacy is evident, yet he has reported experiencing unexpected clarity and well-being after trying the injections himself. He admits to having more questions than answers regarding the treatment's mechanisms and effects.

Conboy’s research background includes a significant tenure at UC Berkeley, where she investigated how youthfulness could potentially be transferred through blood. Her findings have sparked interest from various startups aiming to capitalize on the rejuvenating properties of blood. However, many of these initiatives have yet to produce commercially viable solutions.

Interestingly, while young blood appears to confer benefits to older subjects, the opposite is true: even a single exposure to aged plasma can negatively impact younger animals. This has led Conboy to explore alternative methods, such as the removal and neutral replacement of aged plasma, which showed greater rejuvenation than direct blood exchange.

In light of her transition to Generation Lab, Conboy remains dedicated to developing a drug that can replicate the positive effects observed in her plasma exchange studies. Using a novel microfluidic system to test drug combinations, she aims to identify molecules that can maintain cellular youthfulness in the presence of aged blood components.

As the field of longevity medicine continues to expand, the implications of Generation Lab's findings could be profound, but they must be approached with caution. The quest for a miraculous anti-aging solution remains fraught with uncertainty, and the scientific community will be watching closely.

Source: www.technologyreview.com